Sliwkowski, Mark X.
Genentech
8 papers on CoChatORCID 0009-0001-3656-3142
Most cited papers
- Verified
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology
HER2/EGFR in Cancer ResearchPI3K/AKT/mTOR signaling in cancer
Cited by 6,974
- Verified
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell
HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations
Cited by 873
- Verified
Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib
Carey, K. D., Garton, A. J., Romero, M. S., Kahler, J., Thomson, S., Ross, S., Park, F., Haley, J. D., Gibson, N., & Sliwkowski, M. X. (2006) · Cancer Research
HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations
Cited by 445
- Verified
The erbB3 gene product is a receptor for heregulin.
Carraway, K. L., Sliwkowski, M. X., Akita, R., Platko, J. V., Guy, P. M., Nuijens, A., Diamonti, A. J., Vandlen, R. L., Cantley, L. C., & Cerione, R. A. (1994) · Journal of Biological Chemistry
HER2/EGFR in Cancer ResearchBiotin and Related Studies
Cited by 362
- Verified
Oncogenic ERBB3 mutations in human cancers.
Jaiswal, B. S., Kljavin, N. M., Stawiski, E. W., Chan, E., Parikh, C., Durinck, S., Chaudhuri, S., Pujara, K., Guillory, J., Edgar, K. A., et al. (2013) · Cancer Cell
HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations
Cited by 350
- Verified
Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice
Jumbe, N. L., Xin, Y., Leipold, D. D., Crocker, L., Dugger, D., Mai, E., Sliwkowski, M. X., Fielder, P. J., & Tibbitts, J. (2010) · Journal of Pharmacokinetics and Pharmacodynamics
HER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies Research
Cited by 119
- Verified
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients
Hurvitz, S. A., Betting, D. J., Stern, H. M., Quinaux, E., Stinson, J., Seshagiri, S., Zhao, Y., Buyse, M., Mackey, J., Driga, A., et al. (2012) · Clinical Cancer Research
HER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies Research
Cited by 115
- Verified
Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose
Kamath, A. V., Lu, D., Gupta, P., Jin, D., Xiang, H., Wong, A., Leddy, C., Crocker, L., Schaefer, G., Sliwkowski, M. X., et al. (2012) · Cancer Chemotherapy and Pharmacology
Monoclonal and Polyclonal Antibodies ResearchHER2/EGFR in Cancer Research
Cited by 41
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free